Form D · Biotechnology
Allosteros Therapeutics Inc.
Palo Alto, X1 · CIK 0001503753
Offering snapshot reported Aug 24, 2012 · SEC filing
- Reported sold
- $286K Offering amount: $286K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 1, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2012 | Initial | $286,000 | No comparison | 1 | SEC filing |
| Oct 18, 2010 | Initial | $1,025,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-183182
Source: Form D, filed Aug 24, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Anderson | Director |
| Howard Schulman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
560 Pena Court
Palo Alto, X1, 94306
Palo Alto, X1, 94306